Screening for Albuminuria Discordance With Preserved eGFR: Clinical Implications and Evidence-Based Approaches

Abstract

Albuminuria discordance with preserved estimated glomerular filtration rate (eGFR) is an increasingly recognized phenomenon in nephrology, marked by the presence of elevated urinary albumin excretion in patients whose eGFR remains within the normal range. This clinical scenario is particularly relevant for primary care and specialist practitioners aiming to implement early interventions against chronic kidney disease (CKD) progression and associated cardiovascular risks. This review synthesizes epidemiological data, elucidates underlying mechanisms, discusses diagnostic strategies, and highlights current and emerging management pathways, with an emphasis on practical guideline-driven approaches for healthcare professionals.

Introduction

Kidney disease screening traditionally relies on eGFR and albuminuria as complementary biomarkers. While reduced eGFR consistently signals advanced nephron loss, albuminuria can precede eGFR decline, representing early glomerular injury. The discordant finding of albuminuria in patients with preserved eGFR poses diagnostic and therapeutic challenges but provides a critical window for intervention. Understanding the epidemiology, pathophysiology, and clinical significance of this discordance is essential for optimizing kidney and cardiovascular outcomes in at-risk populations.

Epidemiology / Disease Burden

Population-based studies, including data from the National Health and Nutrition Examination Survey (NHANES), estimate that up to 8–10% of adults may exhibit albuminuria with normal eGFR. This subgroup is frequently underdiagnosed, as screening protocols often prioritize eGFR reduction. Albuminuria discordance is notably prevalent among individuals with diabetes, hypertension, metabolic syndrome, and advancing age. Epidemiological evidence indicates that these patients have a heightened risk for both CKD progression and cardiovascular events compared to those with normal albumin excretion, even when eGFR remains preserved. The disease burden is further magnified by the silent nature of early-stage albuminuria, underscoring the importance of active screening strategies in high-risk populations.

Pathophysiology

The pathogenesis of albuminuria discordant with preserved eGFR involves glomerular endothelial dysfunction, altered podocyte integrity, and increased glomerular permeability. In early diabetic nephropathy and hypertensive nephrosclerosis, microvascular injury disrupts the glomerular filtration barrier, allowing albumin leakage without immediate nephron loss or reduced filtration capacity. Tubulointerstitial mechanisms, such as impaired tubular reabsorption of filtered albumin, may also contribute. Genetic susceptibility, oxidative stress, systemic inflammation, and activation of the renin-angiotensin-aldosterone system (RAAS) are implicated in the development and persistence of albuminuria before eGFR decline.

Risk Factors

Major risk factors for albuminuria with preserved eGFR include poorly controlled diabetes mellitus, systemic hypertension, obesity, metabolic syndrome, atherosclerosis, smoking, and a family history of CKD. Ethnic disparities exist, with higher prevalence observed in African American, Hispanic, and South Asian populations. Use of nephrotoxic medications, advanced age, and chronic inflammatory conditions further elevate risk. Early identification of these risk factors is crucial for targeted screening and prevention strategies.

Clinical Features

Albuminuria in the context of preserved eGFR is typically asymptomatic. Clinical features, when present, are often related to the underlying systemic disease (e.g., hypertension, diabetes) rather than direct renal symptoms. Over time, persistent albuminuria can herald progressive kidney injury, manifesting as hypertension, edema, or subtle changes in urine output. Importantly, even in the absence of overt CKD symptoms, albuminuria serves as an independent marker for endothelial dysfunction and heightened cardiovascular risk.

Diagnosis

Diagnosis hinges on the detection of elevated urine albumin excretion, most commonly assessed by the urine albumin-to-creatinine ratio (UACR) in a spot urine sample. The threshold for abnormal albuminuria is typically set at UACR ≥30 mg/g. Repeat testing is recommended to confirm persistence over at least three months, thereby distinguishing transient from chronic albuminuria. Simultaneous assessment of eGFR, calculated from serum creatinine using CKD-EPI or MDRD equations, is necessary to confirm the discordant pattern. Differential diagnosis should exclude non-renal causes of albuminuria such as urinary tract infection, acute illness, or vigorous exercise.

Treatment & Management

Management focuses on aggressive risk factor modification and renoprotection. Blood pressure control, preferentially with RAAS inhibitors (ACE inhibitors or ARBs), reduces albuminuria and slows CKD progression, even in normotensive patients. Glycemic optimization in diabetes has proven benefits in reducing albuminuria burden. Statin therapy is indicated for cardiovascular risk reduction. Lifestyle interventions, including dietary sodium restriction, weight management, smoking cessation, and regular physical activity, are foundational. Annual monitoring of both UACR and eGFR is recommended to track disease course and therapeutic response. Multidisciplinary care involving nephrology and primary care enhances outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which demonstrate robust reductions in albuminuria and confer protection against both CKD progression and cardiovascular events irrespective of baseline eGFR. Non-steroidal mineralocorticoid receptor antagonists (such as finerenone) have shown promise in reducing albuminuria in diabetic kidney disease. Novel biomarkers (e.g., urinary proteomics, tubular injury markers) are under investigation to refine risk stratification. Machine learning models integrating clinical and laboratory data may enhance early detection and individualized management in the near future.

Guideline Recommendations

International guidelines, including those from KDIGO and the American Diabetes Association, advocate for annual screening of albuminuria in individuals with diabetes, hypertension, or other CKD risk factors, even when eGFR is preserved. Treatment recommendations emphasize RAAS blockade, SGLT2 inhibitors, and comprehensive cardiovascular risk reduction. Early identification and intervention are prioritized to mitigate long-term renal and cardiovascular morbidity. Guidelines also highlight the importance of patient education and shared decision-making in the management of albuminuria discordance.

Conclusion

Screening for albuminuria discordance with preserved eGFR is a pivotal opportunity for early intervention in CKD and cardiovascular risk reduction. Recognizing the epidemiological impact, pathophysiological underpinnings, and clinical implications equips healthcare professionals to implement evidence-based screening, diagnostic, and management strategies. Recent therapeutic advances and evolving guidelines reinforce the critical need for routine albuminuria assessment in at-risk populations. As research progresses, personalized approaches and novel therapies promise to further improve outcomes in this often-overlooked patient subgroup.